The National Health Service (NHS) in the UK has introduced a ‘blood matching’ genetic test, marking a global first in personalised healthcare for patients with sickle cell disorder and thalassaemia.
This new blood group genotyping test is expected to benefit nearly 18,000 eligible individuals by enhancing the accuracy of blood transfusions and minimising the risk of transfusion side effects.
It is designed to address the challenges faced by patients with inherited blood disorders who require regular transfusions.
